The Central Nervous System (CNS) has emerged during the past decade as one of the most important aspects in the treatment of leukaemia and lymphoma. This book attempts to cover this complex subject with chapters on clinical manifestations, pathology, diagnostic techniques, prophylaxis, treatment of overt disease and the complications of treatment.
Most of the book deals with acute lymphoblastic leukaemia of childhood with a short discussion of the problem in acute myelogenous leukaemia, both of children and adults. The problem of CNS involvement in non-Hodgkin lymphoma of children was discussed in the light of one ongoing study at the Memorial Sloan Kettering Cancer Centre. This study showed the success of modern intensive treatment regimes in the condition. Very little is written about the CNS problem of adult patients with non-Hodgkin lymphoma, and perhaps this reflects the lack of information available on the subject, although many centres are now studying the problem more intensively.
Many chapters repeat facts that have already been discussed, and one chapter of 23 pages has 29 tables. More stringent editing would have made the book more readable and intelligible.
Despite the criticism, any doctor who treats leukaemia and lymphoma patients will find the book a worthwhile evening's reading. The book is essentially a series of reviews, and workers in the field will recognize immediately that much of the material has been culled from elsewhere. However, there are many features which make it a useful synopsis of contemporary thinking about the role of the macrophage in neoplasia, and to some extent it redresses the balance which has for so long concentrated upon the attributes of T and B lymphocytes in tumour immunity. G. B. Mackaness contributes a characteristically incisive introductory paper on the role of macrophages in host defence mechanisms and stresses the analogy between resistance to infectious disease and neoplasia which he believes is fundamental to any concept of the host-tumour relationship. This outlook provides an appropriate background for the subsequent discussion (by R. Evans, J. B. Hibbs, M. G. Hanna, K. C. Mclvor, R. Keller and others) of the cytostatic and cytocidal potential of macrophages activated under different experimental conditions, which extends to a study of human tumour destruction (malignant melanoma and breast carcinoma) in vivo by glucan-activated macrophages in the presence of humoral recognition factor (P. W. A. Mansell and N. R. DiLuzio).
The current interest in macrophage content of tumours as an index of host resistance is sustained in several other papers (notably by S. W. Russell and I. J. Fidler) and R. Snyderman and M. C. Pike provide evidence, based on experimental and clinical data, for defective macrophage migration in neoplasia, and for the existence of an inhibitor of macrophage chemotaxis. J. R. David and his colleagues contribute a brief but useful
